These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36990281)

  • 1. Mucosal administration of anti-bacterial antibodies provide long-term cross-protection against Pseudomonas aeruginosa respiratory infection.
    Pitiot A; Ferreira M; Parent C; Boisseau C; Cortes M; Bouvart L; Paget C; Heuzé-Vourc'h N; Sécher T
    Mucosal Immunol; 2023 Jun; 16(3):312-325. PubMed ID: 36990281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration.
    Sécher T; Dalonneau E; Ferreira M; Parent C; Azzopardi N; Paintaud G; Si-Tahar M; Heuzé-Vourc'h N
    J Control Release; 2019 Jun; 303():24-33. PubMed ID: 30981816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
    Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
    Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.
    Gomi R; Sharma A; Wu W; Sung B; Worgall S
    Vaccine; 2017 Dec; 35(51):7174-7180. PubMed ID: 29126807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against respiratory Pseudomonas aeruginosa infection.
    Grimwood K; Kyd JM; Owen SJ; Massa HM; Cripps AW
    Hum Vaccin Immunother; 2015; 11(1):14-20. PubMed ID: 25483510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa.
    Cabral MP; Correia A; Vilanova M; Gärtner F; Moscoso M; García P; Vallejo JA; Pérez A; Francisco-Tomé M; Fuentes-Valverde V; Bou G
    PLoS Pathog; 2020 Feb; 16(2):e1008311. PubMed ID: 32040500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia.
    Sen-Kilic E; Blackwood CB; Huckaby AB; Horspool AM; Weaver KL; Malkowski AC; Witt WT; Bevere JR; Damron FH; Barbier M
    Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33199354
    [No Abstract]   [Full Text] [Related]  

  • 10. Pulmonary Pathogens Adapt to Immune Signaling Metabolites in the Airway.
    Riquelme SA; Wong Fok Lung T; Prince A
    Front Immunol; 2020; 11():385. PubMed ID: 32231665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
    Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
    Front Immunol; 2019; 10():2497. PubMed ID: 31708925
    [No Abstract]   [Full Text] [Related]  

  • 12. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.
    Krause A; Whu WZ; Xu Y; Joh J; Crystal RG; Worgall S
    Vaccine; 2011 Mar; 29(11):2131-9. PubMed ID: 21215829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode.
    Ahmadi TS; Mousavi Gargari SL; Talei D
    Mol Immunol; 2021 Aug; 136():118-127. PubMed ID: 34130152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outer Membrane Vesicles Displaying a Heterologous PcrV-HitA Fusion Antigen Promote Protection against Pulmonary Pseudomonas aeruginosa Infection.
    Li P; Wang X; Sun X; Guan Z; Sun W
    mSphere; 2021 Oct; 6(5):e0069921. PubMed ID: 34612675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Mauch RM; Jensen PØ; Moser C; Levy CE; Høiby N
    J Cyst Fibros; 2018 Mar; 17(2):143-152. PubMed ID: 29033275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
    Meluleni GJ; Grout M; Evans DJ; Pier GB
    J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.
    Cripps AW; Dunkley ML; Clancy RL
    Infect Immun; 1994 Apr; 62(4):1427-36. PubMed ID: 8132349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat.
    Dunkley ML; Rajyaguru S; McCue A; Cripps AW; Kyd JM
    FEMS Immunol Med Microbiol; 2003 Oct; 39(1):37-44. PubMed ID: 14556994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
    Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.